{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fproactive-interviews-for-investors.simplecast.com%2Fepisodes%2F2026-03-02-ataibeckley-WgnhiLkm","width":444,"version":"1.0","type":"rich","title":"AtaiBeckley NV reports encouraging Phase 2a data for EMP-01 in social anxiety","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/92f9cc71-7d4c-4ec0-a2f3-6a6b31027b4c/3fd3b604-35cf-4701-acde-0f1fdf33d67a/square-with-type.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"AtaiBeckley NV CEO Dr Srinivas Rao joined Steve Darling from Proactive to discuss topline results from the company’s exploratory, double-blind, placebo-controlled Phase 2a trial evaluating EMP-01 in adults with Social Anxiety Disorder (SAD).\n\nThe first-in-patient study met its primary safety objective and delivered encouraging secondary and exploratory efficacy signals in what management described as a highly severe, difficult-to-treat patient population.\n\nRegarding safety, Rao said EMP-01 demonstrated a favorable and manageable tolerability profile. No serious adverse events were reported, and there were no cases of treatment-emergent suicidal behavior or intent. Most adverse events were mild to moderate in nature and resolved without medical intervention.\nOn efficacy measures, EMP-01 produced a numerically greater reduction in symptoms than placebo as measured by the Liebowitz Social Anxiety Scale (LSAS). At Day 43, the least squares mean reduction from baseline was -28.53 points for EMP-01 compared to -16.67 points for placebo. While the study was not powered for statistical significance, the placebo-adjusted reduction of 11.85 points (Hedges’ g = 0.45; one-tailed p-value = 0.036) is consistent with a moderate treatment effect size and suggests clinically meaningful improvement.\n\nImportantly, symptom reductions observed at the six-week endpoint—after just two doses of EMP-01—were comparable in magnitude, in cross-trial comparisons, to improvements typically reported after 8 to 12 weeks of daily SSRI or SNRI therapy in registration studies.\n\nOn the Clinical Global Impression-Improvement (CGI-I) scale, 49% of patients treated with EMP-01 were rated as “very much improved” or “much improved,” compared to 15% in the placebo group. This 34-percentage-point difference corresponds to a Number Needed to Treat (NNT) of 2.95 (95% CI: 1.84–7.42), indicating a meaningful level of global clinical improvement.\n\nRao noted that more detailed analyses will be presented at upcoming scientific meetings and will inform the next stages of EMP-01’s clinical development program.\n\n#proactiveinvestors #ataibeckley #nasdaq #atai #clinicaltrial #bpl003 #depression #EMP01 #SocialAnxietyDisorder #SAD #ClinicalTrials #Phase2a #BiotechNews #DrugDevelopment #MentalHealthInnovation #CNSResearch #Neuroscience #PharmaPipeline #ClinicalResearch #LiebowitzScale #CGII #TreatmentInnovation #HealthcareInvesting #EmergingTherapies #BiotechInvestors\n\n"}